Literature DB >> 10620549

Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses.

R Ouseph1, M E Brier, R A Ward.   

Abstract

Anticoagulation with heparin is performed to prevent clotting during dialysis. However, heparin doses are usually determined empirically, and dialyzer clotting is a common reason for discarding reused dialyzers. We hypothesized that using a population pharmacodynamic model to determine individual heparin doses would improve dialyzer reuse rates. A previously published model was used to determine the loading dose and infusion rate of heparin needed to increase the intradialytic whole-blood clotting time to 150% of the predialysis value. The effectiveness of the model was assessed by comparing dialyzer reuse rates and delivered Kt/V(urea) before and after implementation of the model in 22 chronic hemodialysis patients. As an additional control, a similar group of 22 patients were followed up during the same period without adjustment of their heparin doses. Implementation of the model resulted in no change in the average loading dose (2,382 +/- 628 versus 2,425 +/- 908 IU; P = not significant) or average infusion rate (1,398 +/- 367 versus 1,393 +/- 532 IU/h; P = not significant) of heparin. However, individual patients required changes in loading dose or infusion rate. Dialyzer reuse rates increased significantly over time in the treatment group but remained unchanged in the control group (P < 0.003). Kt/V(urea) remained unchanged throughout the study period in both patient groups. From these data, we conclude that the use of a heparin model can improve dialyzer reuse rates without compromising the delivered dose of dialysis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10620549     DOI: 10.1016/S0272-6386(00)70306-4

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

Review 1.  Unfractionated heparin for hemodialysis: still the best option.

Authors:  Robert E Cronin; Robert F Reilly
Journal:  Semin Dial       Date:  2010 Sep-Oct       Impact factor: 3.455

Review 2.  What are the anticoagulation options for intermittent hemodialysis?

Authors:  Andrew Davenport
Journal:  Nat Rev Nephrol       Date:  2011-07-05       Impact factor: 28.314

3.  Correlates and variance decomposition analysis of heparin dosing for maintenance hemodialysis in older US patients.

Authors:  Jenny I Shen; Maria E Montez-Rath; Aya A Mitani; Kevin F Erickson; Wolfgang C Winkelmayer
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-02-18       Impact factor: 2.890

Review 4.  Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.

Authors:  Jenny I Shen; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2012-05-05       Impact factor: 8.860

Review 5.  Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments.

Authors:  Andrew Davenport
Journal:  Pediatr Nephrol       Date:  2012-02-29       Impact factor: 3.714

6.  Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery.

Authors:  Zaishen Jia; Ganzhong Tian; Yupeng Ren; Zhiquan Sun; Wei Lu; Xiaotong Hou
Journal:  J Transl Med       Date:  2015-02-01       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.